Pulse Biosciences Q3 2026 Earnings Call - PULSE BIOSCIENCES INC

Financial Performance:

• Q3 2026 revenue reached $395,000, up $86,000 year-over-year, driven by commercial case volume growth within a limited customer base.
• Cost of product revenue was $191,000; the company anticipates gross margins on disposables exceeding 70% at scale.
• Total GAAP costs and expenses totaled $24.7 million (up $4.2 million YoY), while non-GAAP costs and expenses rose to $19.1 million (up $4.5 million YoY), driven by increased clinical trial and personnel expenses.
• GAAP net loss was $23.1 million compared to $19.4 million in the prior year; non-GAAP net loss was $17.5 million versus $13.5 million previously.
• Cash and marketable securities ended the quarter at $189.2 million, providing an approximate two-year operating runway.
• Cash used in operating activities was $15.3 million, lighter than Q2 ($18.7 million) due to payment timing on clinical studies.
• The ATM program raised over $150 million in net proceeds since May, including $95.8 million in Q3, with cumulative dilution under 6%; approximately $64 million of ATM capacity remains.
• Management expects quarterly non-GAAP expenses to increase 15% to 25% above the Q2/Q3 average of ~$20 million in coming quarters, primarily driven by EP catheter activities.

Guidance and Future Outlook:

• Anticipates FDA clearance for the NPulse cardiac catheter with commercial launch readiness targeted for early 2028.
• CE mark approval for the NPulse catheter is expected in Q4 2027, following final patient data readout in Q3 2027 (blended 6/12-month follow-up).
• Enrolled patients in the pivotal Nanopulse AF IDE study are currently in follow-up; final data conversion for PMA submission is projected for Q3 2027.
• Plans to submit the IDE application for a persistent atrial fibrillation (AF) study in Q4 2026.
• Next-generation NPulse catheter (featuring focal electrode capabilities) is on track for first-in-human evaluations in 2027.
• Vibrance technology expects 510K submission for benign thyroid nodules following completion of 6-month and 12-month follow-ups in 2027.

Business Segments and Product Lines:

• NPulse Cardiac Catheter: Pivotal IDE enrollment completed in under six months (169 evaluable patients), finishing three months ahead of schedule; technology enables 5-second single-shot ablation with minimal learning curve.
• European Feasibility: Enrolled >190 patients total, including >155 in the 5-second cohort; 12-month follow-up data for 53 patients shows 96% freedom from AF; plans to present >100 patients with 12-month data at the AF Symposium in early 2027.
• Surgical Clamp (Nano-Clamp): Enrollment accelerating; expected to complete enrollment by end of H1 2027; CE mark submission ongoing with approval expected Q4 2027; first-in-human evaluation of a surgical ablation pen completed with encouraging results.
• Vibrance (Thyroid): PRECISE-BTN study enrolled 100 patients (double design); 86% achieved >50% nodule volume reduction; no serious adverse events; initiating real-world registry and controlled study for benign nodules; expanding indications to primary hyperthyroidism and papillary thyroid microcarcinoma.

Market and Competitive Landscape:

• NSPFA technology is positioned as the only source of nanosecond PFA, protected by a "patent moat" of over 285 owned patents and significant technical know-how.
• Management differentiates NSPFA from microsecond PFA (competitors) and RF ablation, citing superior lesion depth, consistency, and non-thermal mechanism that prevents cell "stunning" and recurrence.
• Market share shifting is observed in the PFA sector; Pulse anticipates rapid share gains due to workflow efficiency (faster procedures, no learning curve) and clinical differentiation, with expectations of sustained market position due to lack of direct NSPFA competition.
• Reimbursement trends (MPPR) and concomitant procedures favor NSPFA due to reduced procedural time, lower complexity, and potential for higher value procedures.

Risks and Challenges:

• Hemolysis Mitigation: Addressed a specific hemolysis-related safety signal in the feasibility study; mitigated via pre-procedure hydration and real-time fluid delivery protocols implemented in the IDE.
• Manufacturing Scale-up: Need to increase production capacity 200-300 fold from current IDE volumes to support commercial launch, requiring vertical integration of console manufacturing and expansion of contract manufacturers for catheters.
• Regulatory Timeline: Dependence on Q3 2027 data readout for FDA submission; any deviation in clinical results or regulatory delays could impact the 2028 launch target.
• Competitive Adoption: While share shifting is occurring, ensuring high yield and efficient manufacturing to service the market is critical to maintaining the competitive advantage against microsecond PFA and RF.

Management Commentary and Tone:

• Tone is highly confident and optimistic, emphasizing "strong execution," "exceptional physician enthusiasm," and the "unprecedented" nature of the clinical differentiation.
• Management views the rapid IDE enrollment (3 months ahead of schedule) as a primary signal of market demand and procedural acceptance.
• Confident in the "first-in-class" status and the durability of market share, citing the unique mechanism of action that creates permanent lesions compared to reversible effects of other technologies.
• Emphasizes strategic flexibility to pursue direct launch or partnership models, with all commercial readiness investments applicable to either scenario.

Analyst Questions and Answers:

• Launch Readiness: Paul LaViola detailed plans to scale manufacturing (internal console, multi-location contract catheter production), add senior commercial competencies, and conduct live physician demonstrations to drive adoption.
• Partnership Strategy: Co-chair Bob Duggan noted that major strategics are watching the data; no specific deals were disclosed, but the company is prepared to partner or launch independently depending on valuation. He emphasized the impossibility of replicating NSPFA without their technology.
• Mapping Integration: The NPulse system was supported by Abbott in the IDE; integration with other top mapping systems (e.g., CARDO) is planned to ensure versatility in the commercial launch.
• Clinical Comparisons: The company is conducting a comparative mechanism of action study to validate lesion differences between nanosecond and microsecond PFA using clinical biomarkers rather than histology.
• Safety Concerns: Reiterated that hemolysis risks are low and manageable via hydration protocols already standard in the IDE; no new SAEs related to hemolysis are anticipated.
• Prophylactic Market: Expressed belief that NSPFA could expand the surgical ablation market to include prophylactic treatment for post-operative AF in patients who do not currently have preoperative AF, due to the technology's speed and safety in frail populations.

Other Key Points:

• The company has completed enrollment in the PRECISE-BTN study for thyroid nodules ahead of the 12-month follow-up schedule, with preliminary data showing high efficacy and safety.
• Exploration of NSPFA applications in ventricular tachycardia (VT) and premature ventricular contractions (PVCs) is underway with preclinical prototype demonstrations.
• Management highlighted a specific EU data readout at the AF Symposium in early 2027 to provide high-profile validation of the 12-month freedom from AF (expected >90%).
• The company is actively building "commercial readiness" capabilities, including supply chain planning and market segmentation, to support a potential launch in early 2028.